Minocycline and doxycycline are not beneficial in a model of Huntington's disease

Annals of Neurology

Volumn 54, Issue 2, 2003, Pages 186-196

  Smith, Donna L ^a   Woodman, Benjamin ^a   Mahal, Amarbirpal ^a   Sathasivam, Kirupa ^a   Ghazi Noori, Shabnam ^a   Lowden, Philip A S ^b   Bates, Gillian P ^a,c   Hockly, Emma ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF EXETER   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; HUNTINGTIN; MINOCYCLINE; TETRACYCLINE;

AMYLOIDOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BEHAVIOR DISORDER; BRAIN SLICE; CLINICAL RESEARCH; CONTROLLED STUDY; DEMENTIA; DISEASE MODEL; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FATALITY; FEMALE; GENETIC DISORDER; HIPPOCAMPUS; HUNTINGTON CHOREA; INHIBITION KINETICS; MALE; MOTOR DYSFUNCTION; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PERSONALITY DISORDER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION;

ANIMALS; ANTI-BACTERIAL AGENTS; BEHAVIOR, ANIMAL; DOXYCYCLINE; FEMALE; GENOTYPE; HIPPOCAMPUS; HUNTINGTON DISEASE; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; MALE; MICE; MINOCYCLINE; MUSCULOSKELETAL EQUILIBRIUM; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; ORGAN CULTURE TECHNIQUES; PEPTIDES; PHENOTYPE; TETRACYCLINE;

EID: 0042845880     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10614     Document Type: Article

References (47)

1. Bates GP, Harper PS, Jones AL, editors. Huntington's disease. Oxford: Oxford University Press, 2002.
2. Myers RH, Marans KS, MacDonald ME. Huntington's disease. In: Wells RD, Warren ST, eds. Genetic instabilities and hereditary neurological diseases. San Diego: Academic Press, 1998:301-323.
3. DiFiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997;277:1990-1993.
4. Becher MW, Kotzuk JA, Sharp AH, et al. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol Dis 1998;4:387-397.
5. Gutekunst CA, Li SH, Yi H, et al. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci 1999;19:2522-2534.
6. Carter RJ, Lione LA, Humby T, et al. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 1999;19:3248-3257.
7. Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996;87:493-506.
8. Davies SW, Turmaine M, Cozens BA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997;90:537-548.
9. Ferrante RJ, Andreassen OA, Dedeoglu A, et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 2002;22:1592-1599.
10. Dedeoglu A, Kubilus JK, Jeitner TM, et al. Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 2002;22:8942-8950.
11. Schiefer J, Landwehrmeyer GB, Luesse HG, et al. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Mov Disord 2002;17:748-757.
12. Ferrante RJ, Andreassen OA, Jenkins BG, et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 2000;20:4389-4397.
13. Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000;6:797-801.
14. Andreassen OA, Ferrante RJ, Dedeoglu A, Beal MF. Lipoic acid improves survival in transgenic mouse models of Huntington's disease. Neuroreport 2001;12:3371-3373.
15. Luesse HG, Schiefer J, Spruenken A, et al. Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus. Behav Brain Res 2001;126:185-195.
16. Andreassen OA, Ferrante RJ, Huang HM, et al. Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease. Ann Neurol 2001;50:112-117.
17. Andreassen OA, Dedeoglu A, Ferrante RJ, et al. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol Dis 2001;8:479-491.
18. Schilling G, Becher MW, Sharp AH, et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 1999;8:397-407.
19. Reddy PH, Williams M, Charles V, et al. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet 1998;20:198-202.
20. Laforet GA, Sapp E, Chase K, et al. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J Neurosci 2001;21:9112-9123.
21. Hodgson JG, Agopyan N, Gutekunst CA, et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999;23:181-192.
22. Lin CH, Tallaksen-Greene S, Chien WM, et al. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet 2001;10:137-144.
23. Shelbourne PF, Killeen N, Hevner RF, et al. A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum Mol Genet 1999;8:763-774.
24. Wheeler VC, Auerbach W, White JK, et al. Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum Mol Genet 1999;8:115-122.
25. Levine MS, Klapstein GJ, Koppel A, et al. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J Neurosci Res 1999;58:515-532.
26. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000;101:57-66.
27. Hanemaaijer R, Visser H, Koolwijk P, et al. Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells. Adv Dent Res 1998;12:114-118.
28. Yrjanheikki J, Keinanen R, Pellikka M, et al. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 1998;95:15769-15774.
29. Du Y, Ma Z, Lin S, et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 2001;98:14669-14674.
30. Yrjanheikki J, Tikka T, Keinanen R, et al. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Nati Acad Sci USA 1999;96:13496-13500.
31. Kriz J, Nguyen MD, Julien JP. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002;10:268-278.
32. Tikka TM, Koistinaho JE. Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol 2001;166:7527-7533.
33. Tagliavini F, Forloni G, Colombo L, et al. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J Mol Biol 2000;300:1309-1322.
34. Forloni G, Colombo L, Girola L, et al. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett 2001;487:404-407.
35. Andersson H, Alestig K. The penetration of doxycycline into CSF. Scand J Infect Dis Suppl 1976;9:17-19.
36. Wellington CL, Ellerby LM, Hackam AS, et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem 1998;273:9158-9167.
37. Wellington CL, Hayden MR. Caspases and neurodegeneration: on the cutting edge of new therapeutic approaches. Clin Genet 2000;57:1-10.
38. Rideout HJ, Stefanis L. Caspase inhibition: a potential therapeutic strategy in neurological diseases. Histol Histopathol 2001;16:895-908.
39. Smith DL, Portier R, Woodman B, et al. Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles. Neurobiol Dis 2001;8:1017-1026.
40. Mangiarini L, Sathasivam K, Mahal A, et al. Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation. Nat Genet 1997;15:197-200.
41. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990;9:811-818.
42. Axisa B, Naylor AR, Bell PR, Thompson MM. Simple and reliable method of doxycycline determination in human plasma and biological tissues. J Chromatogr B Biomed Sci Appl 2000;744:359-65.
43. Hockly E, Woodman B, Mahal A, et al. Standardization and statistical approaches to therapeutic trials in the R6/2 mouse. Brain Res Bull (in press).
44. Sathasivam K, Woodman B, Mahal A, et al. Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington's disease (HD) transgenic mice and HD patients. Hum Mol Genet 2001;10:2425-2435.
45. Sathasivam K, Hobbs C, Turmaine M, et al. Formation of polyglutamine inclusions in non-CNS tissue. Hum Mol Genet 1999;8:813-822.
46. Ona VO, Li M, Vonsattel JP, et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 1999;399:263-267.
47. Huntington's Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001;57:397-404.